Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) thera...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048925000020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688070530531328 |
|---|---|
| author | Gen Hasegawa Noriharu Nakagawa Yoshimichi Ueda Masahide Yamazaki |
| author_facet | Gen Hasegawa Noriharu Nakagawa Yoshimichi Ueda Masahide Yamazaki |
| author_sort | Gen Hasegawa |
| collection | DOAJ |
| description | Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) therapy for anaplastic large cell lymphoma (ALCL) and responded to retreatment with BV monotherapy. This case suggests that CD30+ PTCL emerging shortly after BV-CHP therapy may respond to retreatment with BV monotherapy, even if the phenotype differs from the initial diagnosis. |
| format | Article |
| id | doaj-art-3677edb702e14645be0f4c77c8adb6b2 |
| institution | DOAJ |
| issn | 2213-0489 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-3677edb702e14645be0f4c77c8adb6b22025-08-20T03:22:08ZengElsevierLeukemia Research Reports2213-04892025-01-012310050010.1016/j.lrr.2025.100500Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomasGen Hasegawa0Noriharu Nakagawa1Yoshimichi Ueda2Masahide Yamazaki3Department of Hematology, Keiju Medical Center, Nanao, Ishikawa, JapanDepartment of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan; Corresponding author at: Department of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan.Department of Pathology, Keiju Medical Center, Nanao, Ishikawa, JapanDepartment of Hematology, Keiju Medical Center, Nanao, Ishikawa, JapanBrentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) therapy for anaplastic large cell lymphoma (ALCL) and responded to retreatment with BV monotherapy. This case suggests that CD30+ PTCL emerging shortly after BV-CHP therapy may respond to retreatment with BV monotherapy, even if the phenotype differs from the initial diagnosis.http://www.sciencedirect.com/science/article/pii/S2213048925000020Peripheral T-cell lymphomaBrentuximab vedotinRetreatmentDifferent phenotype |
| spellingShingle | Gen Hasegawa Noriharu Nakagawa Yoshimichi Ueda Masahide Yamazaki Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas Leukemia Research Reports Peripheral T-cell lymphoma Brentuximab vedotin Retreatment Different phenotype |
| title | Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas |
| title_full | Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas |
| title_fullStr | Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas |
| title_full_unstemmed | Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas |
| title_short | Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas |
| title_sort | retreatment with brentuximab vedotin for discordant peripheral t cell lymphomas |
| topic | Peripheral T-cell lymphoma Brentuximab vedotin Retreatment Different phenotype |
| url | http://www.sciencedirect.com/science/article/pii/S2213048925000020 |
| work_keys_str_mv | AT genhasegawa retreatmentwithbrentuximabvedotinfordiscordantperipheraltcelllymphomas AT noriharunakagawa retreatmentwithbrentuximabvedotinfordiscordantperipheraltcelllymphomas AT yoshimichiueda retreatmentwithbrentuximabvedotinfordiscordantperipheraltcelllymphomas AT masahideyamazaki retreatmentwithbrentuximabvedotinfordiscordantperipheraltcelllymphomas |